Study record managers: refer to the Data Element Definitions if submitting registration or results information. This study will evaluate the time-to-progression TTP in patients with metastatic breast cancer, receiving 1st line therapy with bevacizumab in combination with paclitaxel and gemcitabine. Secondary objectives will include response rates and overall survival OS. Overall response was determined on the basis of response at the target and non-target lesions, and the appearance of new lesions, as follows.
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Gemzar - FDA prescribing information, side effects and uses
This phase II study evaluated the efficacy and safety of gemcitabine G plus paclitaxel T as first-line therapy in recurrent or metastatic breast cancer. Forty patients, 39 metastatic breast cancer and 1 locally-advanced disease, were enrolled. Their median age was Poor prognostic factors at baseline included visceral involvement Also, 27 A total of cycles median 6; range, 1—10 were administered. Of the 40 enrolled patients, 2 had complete response and 12 partial response, for an overall response rate of
Gemcitabine Completed Phase 2 Trials for Cancer, Breast / Metastatic Breast Cancer (MBC) Treatment
Overview Patients diagnosed with Stage IV or metastatic breast cancers have disease that has spread from the affected breast to one or more distant sites in the body. Historically, metastatic breast cancer has been considered incurable; the goal of treatment has been to provide relief from symptoms and prolong the duration and quality of life. However, there have been some important advances resulting in the addition of many more treatment options for managing this disease.
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles nab-paclitaxel for untreated metastatic pancreatic cancer in adults. Evidence-based recommendations on bevacizumab Avastin in combination with gemcitabine and carboplatin for treating the first recurrence of. Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride Caelyx , paclitaxel, trabectedin Yondelis and gemcitabine